atpsynthase

BTB06584 is an IF1-dependent, selective inhibitor of the mitochondrial F1 Fo-ATPase. BTB06584 is a novel acetohydroxyacid synthase(AHAS) inhibitor, a promising drug target against Mycobacterium tuberculosis (MTB).

PRP020 is a potent and specific inhibitor of mycobacterial ATP synthase, which does not inhibit succinate-driven acidification. It exhibits a MIC95 of 2 μM against M. tuberculosis and remains effective against most resistant mutant strains. PRP020 is highly safe and suitable for use in tuberculosis research.

YHV98-4 is a selective Hv1 channel (Hv1 channel) inhibitor that can cross the blood-brain barrier. It specifically inhibits the Hv1 channel with a half-maximal inhibitory concentration of 1 µM without affecting other ion channels. YHV98-4 decreases the spread of p-tau, enhances ATP production, and promotes microglial mitophagy. By inhibiting the Hv1 channel and reducing ROS production, it alleviates inflammatory pain. Additionally, YHV98-4 enhances the transfer of mitochondria (mitochondria) from microglia to neurons, aiding in the delivery of functional mitochondria, thereby repairing neuronal damage and improving cognitive function. It mitigates inflammation and is applicable in Alzheimer’s disease research.

PROTACEGFRdegrader 15 is a bifunctional EGFR PROTAC degrader composed of Pomalidomide and Gefitinib. It facilitates EGFR degradation through ubiquitin-proteasome dependent proteolysis and autophagic-lysosomal pathways. Additionally, PROTACEGFRdegrader 15 targets ETFA to enhance ATP production. It significantly suppresses tumor growth in Gefitinib-resistant HCC-827 xenograft models.

D-α-Hydroxyglutaric acid disodium [Disodium (R)-2-Hydroxyglutarate] is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases with a Ki of 0.628 mM.

ATP synthase inhibitor 1 is an inhibitor of the c subunit of the F1/FO-ATP synthase complex. It inhibits mitochondrial permeability transition pore (mPTP) opening and does not affect ATP levels.

Gboxin is an inhibitor of oxidative phosphorylation that targets glioblastoma,inhibits the activity of F0F1 ATP synthase, with antitumour activity.

Mtb ATP synthase-IN-1 (compound 6ab) is a potent inhibitor of Mycobacterium tuberculosis (Mtb) ATP synthase (MIC = 0.452-0.499 μg/mL) [1] that can be used in anti-mycobacterium research, showing low cytotoxicity (Vero IC 50 > 64 μg/mL) and acceptable oral bioavailability with good metabolic stability.

Oligomycin A (MCH 32) is an inhibitor of ATP synthase, inhibits oxidative phosphorylation and all the ATP-dependent processes occurring on the coupling membrane of mitochondria.

BMS-199264 hydrochloride is the salt form of BMS-199264.BMS-199264 is a potent and selective inhibitor of mitochondrial F1F0 ATP hydrolase with an IC50=0.5 μM.BMS-199264 is able to inhibit the decline of ATP during myocardial ischemia, reduce myocardial necrosis, and enhance the recovery of myocardial contractile function after reperfusion.

PK095 is a proprietary compound in the guanidine - based F1F0-ATPase inhibitor family.

ATP synthase inhibitor3 (compound PT6) is an orally active inhibitor targeting the F-ATP synthase of Mycobacterium tuberculosis (IC50=0.788 μM). It effectively inhibits the growth of the Mycobacterium tuberculosis H37Rv strain (ATCC-27294) in vitro, depleting intracellular ATP levels at an IC50 of 30 μM.

ATP Synthase Inhibitor 2, a compound targeting Pseudomonas aeruginosa (PA) ATP synthase with an IC50 of 10 μg/mL, fully inhibits the ATP synthesis activity of PA at a concentration of 128 μg/mL [1].

ATP Synthase Inhibitor 2 (Compound 22) TFA is a potent inhibitor of Pseudomonas aeruginosa ATP synthase with an IC50 value of 10 μg/mL. It effectively halts ATP synthesis in Pseudomonas aeruginosa at a concentration of 128 μg/mL [1].